Login

NON-SUBSCRIBER OPTIONS
FREE TRIAL   |   NEWSSTAND

Home

GET 30 DAYS FREE

The next health policy debate begins now, and the future direction of health reform seems more uncertain than ever. Now is the time to take advantage of the detailed, forward-looking reporting that only Inside Health Policy delivers.

Sign up for 30 days of no-obligation access for all the essential news during this critical time.

Top Story

GOP Leadership Plans To Bring Graham-Cassidy To Floor Next Week

Senate Majority Leader Mitch McConnell (R-KY) plans to bring the health care overhaul bill by GOP Sens. Bill Cassidy (LA) and Lindsey Graham (SC) to a floor vote next week, although it isn’t clear whether 50 Republican senators support the measure as GOP aides report confusion about how the bill would affect their states.

Latest News

CMS Includes Drug Pay Among Areas On Which It Seeks Advice

CMS is requesting advice for designing demonstrations, including pilots on new Medicare and Medicaid drug payment models, but House Republicans are warning their former colleague HHS Secretary Tom Price about messing with Part B drug reimbursement.

2019 Exchange Policy Rules Under Review At OMB

The 2019 Draft Notice of Benefit and Payment Parameters (NBPP), which will set policy for qualified health plans participating in the exchanges, is now under review by the White House Office of Management and Budget.

Lawmakers Urge FDA To Rewrite 'Deemed To Be A License' Biosimilar Guide

Congressional Diabetes Caucus Co-chairs Diana DeGette (D-CO) and Tom Reed (R-NY) wrote to FDA Commissioner Scott Gottlieb Wednesday (Sept. 20) urging the agency to revise guidance on the Biologics Price Competition Innovation and Act (BPCIA)'s “deemed to be a license” provisions, arguing FDA's existing policy discourages market entry for lower price insulin products.

DOJ Sides With Biosimilars In Follow Up To Amgen v. Sandoz Case

The United States government has once again sided with the biosimilar industry in the latest iteration of litigation surrounding the so-called patent-dance provisions of the Biologics Price Competition and Innovation Act -- arguing in a remanded portion of the highly watched Amgen v. Sandoz Supreme Court case that no additional remedies are available under state law for non-compliance with the patent dance.

CSPI, NCL, FDA Jointly Propose To Stay Menu Labeling Lawsuit

The Center for Science in the Public Interest, National Consumers League and FDA agreed Friday (Sept. 15) to ask the United States District Court for the District of Columbia to stay the advocacy groups' menu labeling lawsuit, citing FDA Commissioner Scott Gottlieb's promise to issue new guidance on menu labeling by the end of the year and not alter the underlying rule as instrumental to reaching the agreement.

Hospitals Push For Two-Year Delay Of Medicaid DSH Cuts

Hospitals are urging lawmakers to support a bipartisan congressional push spearheaded by Reps. Eliot Engel (D-NY), John Culberson (R-TX) and Steven Palazzo (R-MS) to delay the Medicaid Disproportionate Share Hospital payment cuts -- which are set to kick in Oct. 1 -- by another two years.

Gottlieb: Congress Should Regulate LDTs, LDT Community Should Rethink Marketing

FDA Commissioner Scott Gottlieb said that Congress should legislatively lay out the government's role in overseeing diagnostic tests, and that the broader diagnostic testing community should work together to understand how to commercialize tests so they better benefit patients.

Read More →